Details of Disease

General Information of Disease (ID: DIS9WYLA)

Disease Name	Pseudomonas infection
Synonyms	Pseudomonas disease or disorder; Pseudomonas infectious disease; Pseudomonas caused disease or disorder
Disease Class	1B92: Glanders
Definition	Infections with bacteria of the genus pseudomonas.
Disease Hierarchy	DIS5QJ9S: Bacterial infection DISEM33Q: Infectious disease DIS9WYLA: Pseudomonas infection
ICD Code	ICD-11 ICD-11: 1B92 ICD-10 ICD-10: A24, A24.0 Expand ICD-9 001,002,003,004,005,006,007,008,009,010,011,012,013,014,015,016,017,018,019,020,021,022,023,024,025,026,027,028,029,030,031,032,033,034,035,036,037,038,039,040,041,042,043,044,045,046,047,048,049,050,051,052,053,054,055,056,057,058,059,060,061,062,063,064,065,066,067,068,069,070,071,072,073,074,075,076,077,078,079,080,081,082,083,084,085,086,087,088,089,090,091,092,093,094,095,096,097,098,099,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139
Disease Identifiers	MONDO ID MONDO_0005141 MESH ID D011552 UMLS CUI C0033817 MedGen ID 10993 SNOMED CT ID 63398001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Azlocillin	DMIR5QP	Approved	Small molecular drug	[1]
Cefsulodin	DMQXLF3	Approved	Small molecular drug	[1]
Chlortetracycline	DMCQ6C4	Approved	Small molecular drug	[1]
Colistin	DMMD9QE	Approved	Small molecular drug	[1]
Polymyxin B Sulfate	DMN0LP8	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PseudIgY	DMRUWUZ	Phase 3	NA	[3]
Pseudomonas aeruginosa protein vaccine	DMN0TIK	Phase 3	NA	[4]
Aerucin	DMCK28R	Phase 2	Antibody	[5]
MEDI3902	DMOXKIC	Phase 2	Antibody	[6]
Panobacumab	DMV27SP	Phase 2	Monoclonal antibody	[7]
AB569	DMAH2NH	Phase 1	NA	[8]
ACHN-975	DM5SJO9	Phase 1	NA	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aerugen	DMI0PJK	Discontinued in Phase 3	NA	[10]
Pseudomonas aeruginosa vaccine	DM66PIR	Discontinued in Phase 1	NA	[11]
Cytovaxine	DM1ZILR	Terminated	NA	[13]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 5 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
3-Oxo-C12-(2-amino-cyclohexanone)	DM5CVBM	Preclinical	Small molecular drug	[12]
C30	DMY9F1M	Preclinical	Small molecular drug	[12]
INP1855	DM1G6JT	Preclinical	Small molecular drug	[12]
M64	DM32XJS	Preclinical	Small molecular drug	[12]
RS2-1G9	DM89VIO	Preclinical	Antibody	[12]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 8 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DasKloster 0274-01	DMME75V	Investigative	NA	[14]
GMI-1051	DMVVRN5	Investigative	NA	[14]
KBPA-103	DMXHDDN	Investigative	NA	[14]
MBX-1684	DMJECJ0	Investigative	NA	[14]
MediPhage MRPA	DMW43HU	Investigative	NA	[14]
R-type pyocins	DMZQQQ0	Investigative	NA	[14]
RLP-073	DMUA86Z	Investigative	NA	[14]
XTL-Pseudomonas-mab	DMXJMUM	Investigative	Monoclonal antibody	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CRP	TTWRN6M	moderate	Biomarker	[15]
SLC9A3	TTFZVPO	Strong	Genetic Variation	[16]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
SMOX	DEOH5V3	Strong	Biomarker	[17]
------------------------------------------------------------------------------------

This Disease Is Related to 4 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BRAP	OTB7BAFQ	Strong	Biomarker	[18]
DCTN4	OTM7C943	Strong	Biomarker	[19]
FLG2	OTIIKCFS	Strong	Biomarker	[20]
IMPA1	OTBUVW1Z	Strong	Biomarker	[18]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064028.
3	ClinicalTrials.gov (NCT01455675) Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients. U.S. National Institutes of Health.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007774)
5	ClinicalTrials.gov (NCT02486770) Study of Single Doses of IV Aerucin in Healthy Adults.
6	ClinicalTrials.gov (NCT02255760) Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults. U.S. National Institutes of Health.
7	ClinicalTrials.gov (NCT00851435) Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa. U.S. National Institutes of Health.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	ClinicalTrials.gov (NCT01870245) A Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers. U.S. National Institutes of Health.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007764)
11	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007761)
12	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
13	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014101)
14	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
15	Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.J Antimicrob Chemother. 2009 Sep;64(3):563-6. doi: 10.1093/jac/dkp224. Epub 2009 Jun 26.
16	Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis.Pediatr Pulmonol. 2011 Apr;46(4):385-92. doi: 10.1002/ppul.21372. Epub 2010 Oct 21.
17	Calcium induces tobramycin resistance in Pseudomonas aeruginosa by regulating RND efflux pumps.Cell Calcium. 2017 Jan;61:32-43. doi: 10.1016/j.ceca.2016.11.004. Epub 2016 Nov 20.
18	Nosocomial infections caused by multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase.J Clin Microbiol. 2002 Nov;40(11):4051-5. doi: 10.1128/JCM.40.11.4051-4055.2002.
19	Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.Nat Genet. 2012 Jul 8;44(8):886-9. doi: 10.1038/ng.2344.
20	Skin-Derived C-Terminal Filaggrin-2 Fragments Are Pseudomonas aeruginosa-Directed Antimicrobials Targeting Bacterial Replication.PLoS Pathog. 2015 Sep 15;11(9):e1005159. doi: 10.1371/journal.ppat.1005159. eCollection 2015 Sep.